WAVE Life Sciences (NASDAQ: WVE) saw its stock price plummet 5.36% in pre-market trading on Thursday following the release of its first-quarter 2025 financial results. The biotechnology company reported earnings that fell short of analysts' expectations, triggering a sell-off among investors.
The company reported a quarterly loss of $0.29 per share, missing the consensus estimate of a $0.26 loss. This represents a 20.83% increase in losses compared to the same quarter last year. Revenue also disappointed, coming in at $9.18 million, significantly below the analyst forecast of $12.23 million and marking a 26.82% decrease from the previous year.
Further adding to investor concerns, WAVE Life Sciences reported a net loss of $46.878 million, worse than the estimated $43.2 million loss. The company's income from operations also fell short, posting a loss of $49.804 million against expectations of a $45.9 million loss. Despite these challenges, the company maintains a strong cash position of $243.1 million, which it expects will fund operations into 2027. However, this long-term outlook was not enough to offset the immediate disappointment in quarterly results, leading to the sharp decline in stock price.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.